Overview
Status
Active
Registry date
2014-03-25
Share capital
90,000.00 PLN
Registered address
ul. Jarosława Iwaszkiewicza 37, 82-300 Elbląg, Poland
Financials
Revenue history (in k)
Filing timeliness
5 of 6 financial statements were filed late (the longest delay 214 days for 2024).
- 202530/03/2026
- 202414/02/2026
- 202324/10/2024
- 202231/01/2024
- 202126/09/2022
- 202008/11/2021
Filed on timeDelayFiling deadline
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
Revenue
This companyUSD 111.79kMedianUSD 1.06mAverageUSD 22.40m
Net profit
This companyUSD 18.93kMedianUSD 37.33kAverageUSD 880.24k
Operating costs
This companyUSD 90.60kMedianUSD 922.77kAverageUSD 21.08m
Assets
This companyUSD 612.58kMedianUSD 608.93kAverageUSD 11.85m
Industry
Trademarks
Swisscare Pharma holds 1 active trademark registered with the Polish Patent Office. 1 application is pending. 1 mark has expired or was not registered. The first mark was filed in 2011.
| Mark | Number | Classes | Status | Protected until | |
|---|---|---|---|---|---|
| SwissCare Pharma | Z.382513 | 35, 44 | Protected | Mar 10, 2031 | |
| SwissCare | Z.601131 | 5 | Application pending | – | |
| SwissCare | Z.596193 | 5 | Proceedings discontinued | – |
| Mark | Protected until | |
|---|---|---|
| SwissCare Pharma | Mar 10, 2031 | |
| SwissCare | – | |
| SwissCare | – |
Authorized Representatives
Beata Albertowicz Klikiewicz – Management Board Member
Michał Paweł Klikiewicz – President of the Management Board
Manner of representation
One-person representation.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Beata Agata Albertowicz Klikiewiczage 54 | 1,799 | $24,297.68 | 99.9444% |
Others | 1 | $13.51 | 0.0556% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2014-01-31.
37 1160 2202 0000 0002 5644 2918
64 1140 2004 0000 3002 7936 6292
Debt
No entries in the National Debtors Register (KRZ).
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 2, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $1,282$1,282 | PREZYDENT MIASTA ELBLĄG |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| OwlieS.A. | $17,199,251.89 | owlie.pl | ||
| Integris Medical Polskasp. z o.o. | $159,033.76 | integrismedical.pl | ||
| Geneco Groupsp. z o.o. | $156,220.50 | genecocontact.pl | ||
| Black & Whitesp. z o.o. | $154,866.36 | polonus.pl | ||
| BL Medicasp. z o.o. | $148,305.98 | blmedica.pl | ||
| Screenmedsp. z o.o. | $147,401.05 | screenmed.pl | ||
| Pharmbiopolsp. z o.o. | $99,211.10 | pharmbiopol.com | ||
| Mimic Polandsp. z o.o. | $85,589.70 | mimic.com.pl | ||
| Osteoprofsp. z o.o. | $72,065.80 | osteoprof.pl | ||
| Toto Pharma Polandsp. z o.o. | $66,269.14 | totopharma.com |
Change history
| Date | Event | |
|---|---|---|
| 2020-01-15 | PKD change (Removed: 38 codes) | |
| 2016-05-17 | Address change (Fromborska 23/22, 82-300, Elbląg → Ul. Jarosława Iwaszkiewicza 37, 82-300, Elbląg) | |
| 2014-03-25 | Entered in the register |
FAQ
The main business activity of Swisscare Pharma focuses on wholesale of pharmaceutical goods.
The company was registered in the Polish National Court Register (KRS) on March 25, 2014.
The headquarters is located at: ul. Jarosława Iwaszkiewicza 37, 82-300 Elbląg.
The share capital of the company is PLN 90,000 (approx. $24,311).
The latest available financial statement covers the period from January 1, 2025 to December 31, 2025.
In 2025, the company generated total revenue of $111,787, representing an increase of 45.4% compared to 2024.
Yes, the company recorded a net profit of $18,928 in 2025, meaning the company decreased its profit by 62.5%.
The largest operating cost category falls under other operating costs. This category amounted to $90,601 in 2025, representing 100% of all operating expenses.
Last updated: 2026-10-07